Overview
Description
Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals South Korea
Financials
Key metrics
Market capitalisation, EUR | 21,600.74 m |
EPS, EUR | 1.62 |
P/B ratio | 1.81 |
P/E ratio | 63.85 |
Dividend yield | 0.46% |
Income statement (2024)
Revenue, EUR | 2,413.54 m |
Net income, EUR | 286.79 m |
Profit margin | 11.88% |
What ETF is Celltrion, Inc. in?
There are 105 ETFs which contain Celltrion, Inc.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Celltrion, Inc. is the HSBC MSCI Korea Capped UCITS ETF USD.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.